Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma

Main Article Content

Susanne Koeppen
Jörg Hense
Kay Wilhelm Nolte
Joachim Weis

Abstract

Treatment options in multiple myeloma (MM) based on novel agents are often limited by dose-related neurotoxicity. Bortezomib, a highly active reversible proteasome inhibitor, frequently causes peripheral neuropathy (PN). Bortezomib-induced PN (BIPN) is characterized by a length-dependent, sensory, axonal polyneuropathy (PNP) with predominant small fiber-affection. Following dose reduction or drug discontinuation, BIPN resolves within 3-4 months in the majority of patients. The pathophysiological mechanisms of BIPN are unclear. Rare cases of a severe demyelinating or mixed BIPN with prominent motor involvement have been attributed to autoimmune or inflammatory reactions. A case report, including nerve pathology, is presented of a 59-year-old man with stage III IgG-κ MM who was treated with bortezomib on the occurrence of progressive disease. After the fourth cycle, he developed a painful distal symmetric sensory PNP followed by gait instability and muscle weakness increasing over 3 months despite early cessation of bortezomib.


Neurological examination revealed a distal flaccid tetraparesis mainly of the lower limbs with sensory loss and severe ataxia, electrophysiological features of a mixed axonal-demyelinating PNP, and pathomorphological evidence of neuritis. Steroid treatment was initiated, and partial recovery of the neurological symptoms within 6 months was observed. While a neurotoxic effect may explain the initial distal sensory disturbances, the worsening of neurological dysfunction after bortezomib withdrawal and the clinical pattern with steroid-responsive muscle weakness predominantly of the legs are consistent with an immune-mediated mechanism. This is in line with the sural nerve biopsy findings. Toxic BIPN followed by an immune-mediated BIPN in the same patient has not been reported before.

Article Details

Koeppen, S., Hense, J., Nolte, K. W., & Weis, J. (2022). Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma. Archives of Pathology and Clinical Research, 6(1), 001–004. https://doi.org/10.29328/journal.apcr.1001028
Research Articles

Copyright (c) 2022 Koeppen S, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009; 27: 3518-3525. PubMed: https://pubmed.ncbi.nlm.nih.gov/19528374/

Meregalli C. An Overview of Bortezomib-Induced Neurotoxicity. Toxics. 2015; 3: 294-303. PubMed: https://pubmed.ncbi.nlm.nih.gov/29051465/

Ale A, Bruna J, Calls A, Karamita M, Haralambous S, et al. Inhibition of the neuronal NFkappaB pathway attenuates bortezomib-induced neuropathy in a mouse model. Neurotoxicology. 2016; 55: 58-64. PubMed: https://pubmed.ncbi.nlm.nih.gov/27211850/

Jeter A, Kang Y, Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy. Exp Hematol Oncol. 2012; 1: 20. PubMed: https://pubmed.ncbi.nlm.nih.gov/23211009/

Ale A, Bruna J, Navarro X, Udina E. Neurotoxicity induced by antineoplastic proteasome inhibitors. Neurotoxicology. 2014; 43: 28-35. PubMed: https://pubmed.ncbi.nlm.nih.gov/24525285/

Thawani SP, Tanji K, De Sousa EA, Weimer LH, Brannagan 3rd TH. Bortezomib-associated demyelinating neuropathy--clinical and pathologic features. J Clin Neuromuscul Dis. 2015; 16: 202-209. PubMed: https://pubmed.ncbi.nlm.nih.gov/25996966/

Lees JG, Makker PGS, Tonkin RS, Abdulla M, Park SB, et al. Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. Eur J Cancer. 2017; 73: 22-29. PubMed: https://pubmed.ncbi.nlm.nih.gov/28104535/

Staff NP, Podratz JL, Grassner L, Bader M, Paz J, et al. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology. 2013; 39: 124-131. PubMed: https://pubmed.ncbi.nlm.nih.gov/24035926/

Boyette-Davis JA, Cata JP, Zhang H, Driver LC, Wendelschafer-Crabb G, et al. Follow-up psychophysical studies in bortezomib-related chemo neuropathy patients. J Pain. 2011; 12: 1017-1024. PubMed: https://pubmed.ncbi.nlm.nih.gov/21703938/

Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009; 144: 895-903. PubMed: https://pubmed.ncbi.nlm.nih.gov/19170677/

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study. Lancet Oncol. 2011; 12: 431-140. PubMed: https://pubmed.ncbi.nlm.nih.gov/21507715/

Meregalli C, Marjanovic I, Scali C, Monza L, Spinoni N, et al. High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats. J Neuroinflammation. 2018; 15: 232. PubMed: https://pubmed.ncbi.nlm.nih.gov/30131066/

Xu YL, Zhao WH, Tang ZY, Li ZQ, Long Y, et al. Guillain-Barre syndrome in a patient with multiple myeloma after bortezomib therapy: A case report. World J Clin Cases. 2019; 7: 2905-2909. PubMed: https://pubmed.ncbi.nlm.nih.gov/31616710/

Mauermann ML, Blumenreich MS, Dispenzieri A, Staff NP. A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment. Muscle Nerve. 2012; 46: 970-977. PubMed: https://pubmed.ncbi.nlm.nih.gov/23225391/

Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol. 2008; 119: 2507-2512. PubMed: https://pubmed.ncbi.nlm.nih.gov/18829381/

Saifee TA, Elliott KJ, Rabin N, Yong KL, D'Sa S, et al. Bortezomib-induced inflammatory neuropathy. J Peripher Nerv Syst. 2010; 15: 366-368. PubMed: https://pubmed.ncbi.nlm.nih.gov/21199108/

Schmitt S, Goldschmidt H, Storch-Hagenlocher B, Pham M, Fingerle-Rowson G, et al. Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma. Int J Hematol. 2011; 93: 791-794. PubMed: https://pubmed.ncbi.nlm.nih.gov/21553020/